The primary objective of the present study was to clarify whether ANXA2 is a useful biomarker for distinguishing HCC from cirrhosis; the secondary objective was to evaluate the role of ANXA2 in predicting HCC recurrence following liver transplantation. Here, ANXA2 is linked to hepatocellular carcinoma.